Clinical Trials · NCT00729313

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Name: Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lanreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 111
Start date: Apr 2000
Locations: 19 sites, France, Russia
Primary endpoint: Number of patients with a reduction of fistula drainage volume > 50% of baseline at 72 hours.

View Lanreotide compound reference